Fortress Biotech, Inc. (FBIO) presents an interesting profile, particularly when examining its short interest and institutional ownership trends. The stock currently shows a significant short interest, with 3,128,751 shares shorted, representing 14.23% of its float. The Days to Cover ratio stands at a high 29.30, indicating that it would take nearly a month for short sellers to cover their positions at average trading volumes. This elevated Days to Cover metric often signals potential for increased volatility and, in certain market conditions, a short squeeze scenario.
From an institutional perspective, FBIO has seen a recent decrease in institutional engagement. There are 58 institutional owners holding a total of 3,797,655 shares, but the number of institutional owners declined by 14.71% quarter-over-quarter. Furthermore, institutional shares (long) decreased by 24.64% over the last quarter. Despite this reduction, major funds like Vanguard Group Inc and Nantahala Capital Management, LLC remain among the largest shareholders.
Analyst sentiment appears to be positive, with an average one-year price target of $15.64, ranging from $4.04 to $27.30. Recent analyst actions include reiterated "Buy" or "Overweight" ratings from firms such as Roth MKM, Alliance Global Partners, and Cantor Fitzgerald. However, Fintel's factor scores reveal a mixed picture, with a low Piotroski F-SCORE of 2.00/9, and lower scores for Growth (16.30/100) and Value (20.22/100), while Profitability (50.48/100) and Quality (59.93/100) are closer to average. This divergence between analyst targets and some quantitative factor scores suggests a need for deeper due diligence into the company's fundamentals and future prospects.
